Sangamo Therapeutics, Inc. - SGMO STOCK NEWS

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on August 11 at 2:55 PM Eastern Time. The virtual session will be webcast live, providing investors access to insights about the company's genomic medicines pipeline, which leverages zinc finger genome engineering technology. The presentation will be available for later viewing on Sangamo's website, ensuring that stakeholders can stay informed about its progress and strategies in the clinical-stage biopharmaceutical sector.

Sangamo Therapeutics (SGMO) announced its Q2 2021 financial results, reporting a net loss of $47.2 million or $0.33 per share, up from a loss of $35.9 million in 2020. Q2 revenues reached $27.9 million, a $6.3 million increase year-over-year, attributed to collaboration agreements with Novartis and Biogen. Operating expenses rose to $76.6 million from $59.4 million in Q2 2020. As of June 30, 2021, cash and equivalents totaled $578.9 million. The company reiterated its 2021 expense guidance of $285 million to $305 million.

Sangamo Therapeutics (Nasdaq: SGMO) announced the release of its second quarter 2021 financial results, scheduled for August 5, 2021, after market close. This will be followed by a conference call at 4:30 p.m. ET, open to the public via phone and webcast. During the call, the company will discuss its financial performance and provide updates on its business operations. Dial-in numbers are provided for domestic and international callers, and a replay will be available for one week post-call.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has appointed Prathyusha Duraibabu as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Duraibabu, who previously served as Principal Accounting Officer, brings over 20 years of experience in financial strategy and operations. Her notable contributions include orchestrating a $140 million follow-on offering and aiding collaborations with Biogen and Novartis, raising an additional $425 million. CEO Sandy Macrae highlighted her leadership and experience in enhancing organizational efficiency.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced management will participate in a fireside chat at the Jefferies Healthcare Conference on June 4^th at 11am ET. The session will be available via live webcast on the Sangamo Therapeutics website and will also be accessible after the event. Sangamo is dedicated to advancing genomic medicines, including gene therapy and genome engineering, with aims to transform patient care. For additional details, visit Sangamo's official website.

Sangamo Therapeutics (SGMO) reported Q1 2021 results, highlighting a net loss of $45.9 million or $0.32 per share, slightly more than the $42.9 million loss in Q1 2020. Total revenues surged to $26.3 million from $13.1 million due to license fees and research reimbursements. Key achievements included completing enrollment for the hemophilia A Phase 3 trial and receiving Fast Track Designation from the FDA for SAR445136, a therapy for sickle cell disease. Total operating expenses increased to $72.6 million, influenced by higher clinical and manufacturing costs. Cash reserves decreased to $629.5 million.

Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in two investor conferences in May 2021. The first is the BofA Securities 2021 Health Care Conference, scheduled for May 13 at 1:15 p.m. Eastern Time. The second is the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 9:45 a.m. Eastern Time. Webcast links for these presentations will be available on the company's website under the Investors and Media section. Post-event recordings will also be accessible on the site.

Sangamo Therapeutics (NASDAQ: SGMO) will present data at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 11-14, 2021. The presentations will spotlight their zinc finger technology and its potential applications in neurodegenerative diseases such as ALS and Parkinson’s disease. Key presentations include studies on selective repression of C9ORF72 for ALS and alpha-synuclein repression for Parkinson’s. The company remains optimistic about their technology's impact on difficult-to-treat conditions, despite acknowledging risks associated with clinical development and regulatory approvals.

Sangamo Therapeutics (Nasdaq: SGMO) has announced the release of its first quarter 2021 financial results, scheduled for May 4, 2021, after market close. Following this, the Company will host a conference call at 5:00 p.m. ET to discuss the financial performance and provide updates on its business activities. Participants can join the call via telephone or webcast, with dial-in numbers provided for domestic and international callers.